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PreviewsIdentification of Early Cellular
Immune Factors Regulating Growth
of Malaria Parasites in Humans
In many host-parasite systems, regulatory T cells (CD4+,
CD25+, FOXP3+) have been shown to modulate cellular
immunity and pathology. In this issue of Immunity,
Walther et al. have now shown that following experi-
mental malaria infection of human volunteers, en-
hanced TGF- and T reg responses are associated
with a faster parasite growth rate. The study demon-
strates that regulation of cellular immunity must be
addressed if we are to develop successful interven-
tions.
The ability of cellular immune responses to control the
growth of the blood stages of malaria parasites is
thought to be critical to disease outcome (Grun and
Weidanz, 1983; Good et al., 2005). Although red blood
cells express few if any MHC antigens and cannot be
directly recognized by T cells, it is thought that para-
sites are destroyed by small inflammatory molecules
downstream of T cells activated by presented antigen,
predominantly in the spleen. Since parasite density is
a key index of disease outcome, it is reasonable to ex-
pect that those factors that regulate the cellular im-
mune responses to malaria will have a major bearing
on morbidity and mortality.
However, disease outcome involves more than para-
site killing per se, because inflammatory parasiticidal
molecules may also contribute to disease. Inflamma-
tory cytokines are involved in the pathogenesis of cere-
bral malaria, anemia, and other organ pathologies. In a
rodent model, antibodies to IFN-γ can prevent cerebral
malaria (Grau et al., 1989), and it has been shown that
while CD4+ Th1 cells could transfer resistance to para-
site growth, those mice that received the most T cells
died earliest with weight loss and anemia (Hirunpetch-
arat et al., 1999).
It seems that if inflammatory processes could be ju-
diciously boosted to control parasite growth, disease
might be prevented; alternatively, inhibition of inflam-
matory responses might lessen disease irrespective of
parasite load. In many systems, regulatory T cells have
been shown to determine the balance between pathol-
ogy and the microbial killing that follows activation of
cellular immunity (Belkaid and Rouse, 2005). TGF-β,
often produced during chronic infections, is thought to
be important in T reg induction, function, and survival.
However, its function in malaria immunity and immuno-
pathology is not well understood.
For example, following infection with the rodent para-
site, Plasmodium berghei, TGF-β levels are inversely re-
lated to parasite burden, whereas during P. chabaudi
and P. yoelii infections, levels initially decrease with
increasing parasitemia but then increase (Omer and
Riley, 1998). Recombinant TGF-β therapy could signifi-
cantly reduce parasite load; however, this effect wasnot dose dependent and was difficult to explain given
its antiinflammatory properties. In a separate study of
the correlation of TGF-β levels and parasitemia, Su et
al. (2005) observed that mice coinfected with P. cha-
baudi and a nematode had higher TGF-β levels and a
higher parasite burden than mice infected with P. cha-
baudi alone. In keeping with these data, Hisaeda et al.
(2004), while not examining the TGF-β response, did
observe that depleting T reg cells in vivo enabled mice
to control an otherwise lethal infection with P. yoelii.
These various studies, while somewhat conflicting,
point to a role for TGF-β in regulating parasite burden.
The TGF-β response has also been shown to differ
between mice infected with a virulent Plasmodium
strain and those infected with a benign strain. Thus,
Omer et al. (2003) demonstrated that following infection
with the avirulent P. yoelii 17X, TGF-β levels peaked late
and correlated with reduced parasite density, whereas
infection with the virulent P. yoelii 17XL resulted in an
early TGF-β response, a downregulated Th1 response,
failure to clear parasites, and death. Furthermore, the
TGF-β response per se may dictate whether a given
infection follows a virulent course: blocking TGF-β in
vivo can shorten survival time with only a modest in-
crease in parasitemia (Omer and Riley, 1998). These
data demonstrate a complex duality of immunoregula-
tory effects of TGF-β with respect to parasite burden
and pathology. Defined clinical studies are needed to
gauge the relevance of TGF-β in human malaria.
Walther et al. (2005) have now studied immunological
correlates of parasitemia in 26 individuals (half of whom
had received a candidate liver-stage vaccine) following
experimental infection with genetically identical malaria
sporozoites. While the vaccine did not protect, it pro-
vided the investigators with a relatively large group of
malaria-naive individuals for whom parasite growth
rates were available following infection and in whom
immune responses could be determined. Following in-
fection, half of the individuals demonstrated an early
peak in plasma TGF-β levels, and those individuals had
a significantly higher parasite growth rate. The re-
sponse was unrelated to whether or not the individuals
received the vaccine. The TGF-β response correlated
with a boost in CD25+ FOXP3+ T reg cell numbers. In
vitro depletion of CD25+ cells resulted in an enhanced
proliferative and IFN-γ T cell response to parasite anti-
gens. The data are consistent with early control of para-
site growth by a CD4+ T cell-derived IFN-γ response
that can be modulated by T reg cells downstream of
TGF-β induction.
The study is looking only at the very early regulatory
responses following infection. These may set the
course of the unfolding immune response and ultimate
outcome. However, the effect of the regulatory re-
sponses later in infection may be different but equally
important. Chaiyaroj et al. (2004) observed that TGF-β
levels were lower in individuals with uncomplicated ma-
laria than in healthy controls and lower again in severe
malaria. The infection had progressed much further in
these patients than in the experimental subjects of Wal-
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242ther et al., but the low TGF-β response in cases of se-
vere malaria (who also had the highest parasite bur-
dens) are likely to represent a failure of the regulatory
response to dampen host pathology late in infection.
Understanding the nature of the TGF-β response
throughout infection should yield important insights
into immunity and pathogenesis.
The paper raises many questions relevant to patho-
genesis. Foremost is why only some individuals gener-
ate a TGF-β response and whether such individuals
would ultimately demonstrate a worse outcome (had
the infection been allowed to proceed). The authors
suggest a genetic basis for the variation in response,
but their data do not exclude that the response is
stochastic. This could be explored by reexposing the
same individuals to another infection and observing
whether the same TGF-β response followed. Identifica-
tion of the parasite molecule(s) responsible for stimulat-
ing TGF-β production is an important challenge and
could lead to novel therapies relevant not only to ma-
laria but to many diseases. It is also important to iden-
tify the source of TGF-β. While their data point to
monocytes as a likely source within peripheral blood,
non-blood cells such as hepatocytes cannot be ex-
cluded, particularly since infection commenced with a
sporozoite inoculation, which is immediately followed
by a liver phase. It is also not clear whether TGF-β
transformed conventional CD4+ T cells to become T
regs (Chen et al., 2003) or whether natural T reg cells
are activated by Plasmodium to produce TGF-β.
The demonstration of a correlation between early
parasite growth rates and parameters of immune regu-
lation provides new insight into human immune surveil-
l
p
M
T
P
B
A
S
B
C
U
C
M
G
R
G
b
U
G
H
P
H
K
2
O
O
5
S
S
W
F
aance of malaria that will be invaluable for vaccine and
ossibly drug development to combat malaria.
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